Citri made successful development of Clarithromycin

Citri Co. announced on Dec. 14 that Clarithromycin, an anti-bacterial agent against Helicobacter pylori was successfully developed for the lst time in Korea and the 2nd in the world after Abbott. Its patent registration was also completed.

Citri has put 890 million won of R&D investment for 4 years from 1998 through 20 researchers. Abbott and Citril can enjoy an exclusive marketing activity ...